Chengwu Shen

745 total citations
28 papers, 421 citations indexed

About

Chengwu Shen is a scholar working on Molecular Biology, Pharmacology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Chengwu Shen has authored 28 papers receiving a total of 421 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Pharmacology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Chengwu Shen's work include Antibiotic Resistance in Bacteria (4 papers), Antibiotics Pharmacokinetics and Efficacy (4 papers) and Neurological Disease Mechanisms and Treatments (3 papers). Chengwu Shen is often cited by papers focused on Antibiotic Resistance in Bacteria (4 papers), Antibiotics Pharmacokinetics and Efficacy (4 papers) and Neurological Disease Mechanisms and Treatments (3 papers). Chengwu Shen collaborates with scholars based in China. Chengwu Shen's co-authors include Mei Qi, Lin Wang, Bo Han, Hui Zhang, Guangxi Zhai, Ping Chen, Muyi Yang, Wen Zhang, Jing Zhang and Rui Zhang and has published in prestigious journals such as Biochemical and Biophysical Research Communications, Frontiers in Immunology and Frontiers in Microbiology.

In The Last Decade

Chengwu Shen

28 papers receiving 415 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chengwu Shen China 11 179 70 63 51 46 28 421
Abdulmohsin J. Alamoudi Saudi Arabia 14 193 1.1× 75 1.1× 61 1.0× 25 0.5× 63 1.4× 41 555
Kai Dong China 15 176 1.0× 57 0.8× 75 1.2× 89 1.7× 105 2.3× 32 527
Lavinia Lupuţ Romania 13 203 1.1× 66 0.9× 89 1.4× 75 1.5× 59 1.3× 18 455
Christos Kazazis Greece 7 257 1.4× 68 1.0× 104 1.7× 152 3.0× 29 0.6× 11 554
Vinod Balachandran India 12 315 1.8× 130 1.9× 62 1.0× 138 2.7× 33 0.7× 14 598
Mahmoud M. Zakaria Egypt 15 227 1.3× 38 0.5× 29 0.5× 41 0.8× 15 0.3× 34 604
Minghua Liu China 14 255 1.4× 57 0.8× 116 1.8× 18 0.4× 13 0.3× 39 568
Hee-Jeong Kim South Korea 10 141 0.8× 144 2.1× 132 2.1× 18 0.4× 19 0.4× 25 568
Qiufang Zhang China 13 149 0.8× 23 0.3× 49 0.8× 19 0.4× 25 0.5× 26 419
Yini Cao China 15 163 0.9× 28 0.4× 35 0.6× 15 0.3× 37 0.8× 21 460

Countries citing papers authored by Chengwu Shen

Since Specialization
Citations

This map shows the geographic impact of Chengwu Shen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chengwu Shen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chengwu Shen more than expected).

Fields of papers citing papers by Chengwu Shen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chengwu Shen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chengwu Shen. The network helps show where Chengwu Shen may publish in the future.

Co-authorship network of co-authors of Chengwu Shen

This figure shows the co-authorship network connecting the top 25 collaborators of Chengwu Shen. A scholar is included among the top collaborators of Chengwu Shen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chengwu Shen. Chengwu Shen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Ren, Xiuli, et al.. (2024). A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib. Frontiers in Pharmacology. 15. 1407709–1407709. 7 indexed citations
3.
Wu, Jichao, et al.. (2024). Ceftazidime-avibactam induced renal disorders: past and present. Frontiers in Pharmacology. 15. 1329307–1329307. 5 indexed citations
4.
Shen, Chengwu, Pengfei Jin, Ting Li, et al.. (2023). Safety of butylphthalide and edaravone in patients with ischemic stroke: a multicenter real-world study. Journal of Geriatric Cardiology. 20(4). 293–308. 6 indexed citations
5.
Li, Zhenyu, Lejiao Jia, Hui Tang, Yuemao Shen, & Chengwu Shen. (2023). LZY3016, a novel geldanamycin derivative, inhibits tumor growth in an MDA-MB-231 xenograft model. RSC Advances. 13(20). 13586–13591. 2 indexed citations
6.
Hu, Sheng, Bing Leng, Jinjiao Jiang, et al.. (2023). An HPLC-MS/MS method for determination of sulbactam in human plasma and its pharmacokinetic application in critically ill patients with augmented renal clearance. International Journal of Clinical Pharmacology and Therapeutics. 61(8). 329–338. 1 indexed citations
7.
Leng, Bing, Chengwu Shen, Tiantian Gao, et al.. (2022). Incidence, characteristics and risk factors of hypofibrinogenemia associated with tigecycline: A multicenter retrospective study in China. Frontiers in Pharmacology. 13. 943674–943674. 9 indexed citations
8.
Shen, Chengwu, Jinru Ji, Chaoqun Ying, et al.. (2021). The Monte Carlo Simulation of Three Antimicrobials for Empiric Treatment of Adult Bloodstream Infections With Carbapenem-Resistant Enterobacterales in China. Frontiers in Microbiology. 12. 738812–738812. 3 indexed citations
9.
Leng, Bing, et al.. (2021). Dose optimisation based on pharmacokinetic/pharmacodynamic target of tigecycline. Journal of Global Antimicrobial Resistance. 25. 315–322. 25 indexed citations
10.
Li, Zhenyu, Xingkang Wu, Lejiao Jia, et al.. (2020). Design and synthesis of novel 2-arylbenzimidazoles as selective mutant isocitrate dehydrogenase 2 R140Q inhibitors. Bioorganic & Medicinal Chemistry Letters. 30(9). 127070–127070. 7 indexed citations
11.
Li, Zhenyu, Lejiao Jia, Hui Tang, Yuemao Shen, & Chengwu Shen. (2019). Synthesis and biological evaluation of geldanamycin–ferulic acid conjugate as a potent Hsp90 inhibitor. RSC Advances. 9(72). 42509–42515. 13 indexed citations
12.
Zhang, Rui, Lin Xu, Dong Zhang, et al.. (2018). Cardioprotection of Ginkgolide B on Myocardial Ischemia/Reperfusion-Induced Inflammatory Injury via Regulation of A20-NF-κB Pathway. Frontiers in Immunology. 9. 2844–2844. 41 indexed citations
13.
Zhang, Rui, Zhenyu Li, Chengwu Shen, et al.. (2018). Ginkgolide C Alleviates Myocardial Ischemia/Reperfusion-Induced Inflammatory Injury via Inhibition of CD40-NF-κB Pathway. Frontiers in Pharmacology. 9. 109–109. 26 indexed citations
14.
Zhang, Xiaojian, et al.. (2016). A meta-analysis of the effects of β-adrenergic blockers in chronic heart failure. Experimental and Therapeutic Medicine. 12(4). 2489–2496. 10 indexed citations
15.
Zhang, Wen, et al.. (2015). Prodrug-based nano-drug delivery system for co-encapsulate paclitaxel and carboplatin for lung cancer treatment. Drug Delivery. 23(7). 2575–2580. 43 indexed citations
16.
Yang, Muyi, Jing Wang, Lin Wang, et al.. (2015). Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells. The Prostate. 75(13). 1363–1375. 24 indexed citations
17.
Tang, Hui, Juan Wu, Wen Zhang, et al.. (2015). Design, synthesis and biological evaluation of novel non-azole derivatives as potential antifungal agents. Chinese Chemical Letters. 26(9). 1161–1164. 10 indexed citations
18.
Zhang, Jing, Chengwu Shen, Lin Wang, et al.. (2014). Metformin inhibits epithelial–mesenchymal transition in prostate cancer cells: Involvement of the tumor suppressor miR30a and its target gene SOX4. Biochemical and Biophysical Research Communications. 452(3). 746–752. 72 indexed citations
19.
Qi, Mei, Zhiyan Liu, Chengwu Shen, et al.. (2014). Overexpression of ETV4 is associated with poor prognosis in prostate cancer: involvement of uPA/uPAR and MMPs. Tumor Biology. 36(5). 3565–3572. 27 indexed citations
20.
Shen, Chengwu, et al.. (2014). Identification, Synthesis, and Strategy for the Reduction of Potential Impurities Observed in Dabigatran Etexilate Mesylate Processes. Organic Process Research & Development. 18(6). 744–750. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Abdulmohsin J. Alamoudi Breakdown of academic impact, for papers by Kai Dong Breakdown of academic impact, for papers by Lavinia Lupuţ Breakdown of academic impact, for papers by Christos Kazazis Breakdown of academic impact, for papers by Vinod Balachandran Breakdown of academic impact, for papers by Mahmoud M. Zakaria Breakdown of academic impact, for papers by Minghua Liu Breakdown of academic impact, for papers by Hee-Jeong Kim Breakdown of academic impact, for papers by Qiufang Zhang Breakdown of academic impact, for papers by Yini Cao
Rankless by CCL
2026